AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
AstraZeneca Plc (NASDAQ:AZN) reported fourth-quarter sales of $14.89 billion, up 18% year over year (+19% at constant ...
BioSpace1d
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...
Zacks.com on MSN1d
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus ...
DAVENPORT & Co LLC Sells 518 Shares of AstraZeneca PLC (NASDAQ:AZN)
DAVENPORT & Co LLC decreased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & ...
Healio11d
Metered-dose to dry-powder inhaler switch not often reversed in veterans
A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...
Zacks.com on MSN1d
Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Astrazeneca (AZN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics ...